Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MRVIthis companyMaravai LifeSciences Holdings, Inc.	$8.00	-3.57×	2.22×	2.54×	-4.86×	-66.3%	18.0%	-3.6%	-70.4%	-61.6%	-0.9%	-15.0%	0.17×	1.23×	-0.25×	6.6×	0.0%	4	4.88	1	C-
AZTAAzenta, Inc.	$40.14	-23.54×	0.76×	2.21×	21.18×	-69.9%	45.5%	-1.9%	-9.4%	-3.2%	2.1%	2.9%	0.06×	-3.12×	0×	2.98×	0.0%	4	3.8	2	C+
BIOBio-Rad Laboratories, Inc.	$390.14	10.87×	1.11×	3.2×	7.65×	-146.4%	52.0%	10.5%	29.4%	10.2%	2.0%	4.5%	0.21×	0.83×	5.52×	5.62×	0.0%	7	3.65	3	B
LABStandard BioTools Inc.	$0.69	-6.4×	1.15×	5.72×	-4.68×	-325.1%	49.9%	-109.3%	-87.8%	-17.7%	-12.2%	-16.9%	0.07×	1.02×	-3,588.65×	4.19×	0.0%	3	-0.44	2	C+
NEOGNeogen Corporation	$12.09	-223×	0.93×	2.23×	15.45×	-121.0%	46.9%	-2.5%	-0.9%	-0.4%	-0.6%	1.6%	0.38×	3.69×	-0.38×	3.82×	0.0%	6	1.45	2	C
PACBPacific Biosciences of California, Inc.	$2.33	-1.03×	104.87×	3.51×	-8.23×	-472.5%	31.7%	-348.5%	-341.5%	-10214.5%	-76.4%	-20.3%	142.07×	-4.56×	-80.18×	6.89×	0.0%	2	-4.47	2	B-
Peer median	—	-6.4×	1.11×	3.2×	7.65×	-146.4%	46.9%	-2.5%	-9.4%	-3.2%	-0.6%	1.6%	0.21×	0.83×	-0.38×	4.19×	0.0%	4	1.45	2	—